Keywords
Streptococcus pneumoniae, serotype, antimicrobial resistance, 13-valent pneumococcal conjugate vaccine, China
This article is included in the Pathogens gateway.
This article is included in the Antimicrobial Resistance collection.
Streptococcus pneumoniae, serotype, antimicrobial resistance, 13-valent pneumococcal conjugate vaccine, China
Pneumonia accounts for 15% of all deaths of children under 5 years old, killing 808,694 children in 2017; Streptococcus pneumoniae is the most common cause of bacterial pneumonia in children1. Although the widespread use of PCVs has decreased the burden of invasive pneumococcal disease (IPD)2, S. pneumoniae is still a substantial issue because immunization causes serotype changes, the available PCVs are costly, and widespread antibiotic use during the last decades has resulted in drug-resistant strains of S. pneumoniae3. The introduction of pneumococcal vaccines has decreased the incidence of drug-resistant strains in some areas4. However, because of the widespread abuse of antibiotics and limited use of vaccines in many Asian countries, antibiotic resistance remains a very serious problem in Asia.
In China, pneumococcal disease is a major cause of morbidity and mortality in children5,6. Although PCV7 was licensed in China in 2008, it was not included in the national immunization program. The coverage rate of this vaccine is low; only 10% of Chinese children received PCV7 in 2016.7 An analytical decision model indicated that the use of PCV7 could have prevented more than 16.2 million cases of pneumococcal disease and 709,411 deaths in China during the 10 years after the vaccine’s introduction8. Similarly, although PCV13 was licensed for optional use in November 2016, it is not widely used because of low awareness and the high price of the vaccine.
China still lacks a systematic surveillance program for pneumococcal diseases. To date, studies analyzing serotypes and antimicrobial resistance of S. pneumoniae have not specified the date of introduction or the type of PCV. This study may provide useful information on the impact of PCV13 in China.
In this study, we aim to investigate how S. pneumoniae serotypes are distributed and to map antimicrobial resistance in children under age 5 years in China since the introduction of PCV13. We formulated our main review question using the SPICE framework (setting, perspective, intervention, comparison, evaluation). The framework and key elements are summarized in Table 1.
All types of studies are eligible for inclusion in our review if they meet all 5 of the following criteria: (1) Analyze serotype distribution or antimicrobial resistance to S. pneumoniae in China; (2) contain information on the impact of PCV13 in China; (3) include only subjects less than 5 years of age; (4) be written in English or Chinese; and (5) be published between November 2016 and February 2020.
Two investigators will independently evaluate the titles and abstracts of all articles according to the inclusion criteria. Any disagreement will be resolved through discussion among team members, and if there is difficulty related to the selection of studies, the criteria will be refined.
The study will begin in March 2020 and will include searches of PubMed, the China National Knowledge Infrastructure (CNKI), Wanfang Med Online, the WHO database, and the China Antimicrobial surveillance Network (CHINET).
PubMed is the largest database of medical information in the world. Created in 1946 by the National Library of Medicine, it includes the MEDLINE database, which contains information from more than 24 million articles published in 5,600 journals in 30 languages.
CNKI, as the largest, most-used online academic library in China, is a key national information construction project under the lead of Tsinghua University. It is the most comprehensive repository of knowledge in China, with more than 16 million website visits each day. In 2019, the website recorded 2.3 billion full-text downloads.
Wanfang Med Online aims to become a type of bridge that connects medical professionals and researchers in China with medical professionals and researchers around the world. At present, the English version includes about 200 selected Chinese medical journals including the top 115 medical journals published by the Chinese Medical Association, 1 Science Citation Index (SCI) journal, 7 Science Citation Index Expanded (SCIE) journals, and 60 Medline journals.
The search strategy will be based on a combination of three elements: the condition of interest, the specified intervention, and the geographical region (Figure 1). The use of "OR" and "AND" to combine key words is shown in Table 2.
Data management. Retrieved records will be automatically or manually exported into EndNote.
Selection process. The search and selection process will be documented in a PRISMA flowchart9. Screening and selection will be done in duplicate by two members of the review team. Any discrepancies discovered during screening of full-text papers will be discussed with the principal investigator.
Data collection process. Two investigators will independently extract data from the studies that meet the inclusion criteria. Any disagreement will be resolved through discussion, and if they do not agree, the principal investigator will arbitrate. If data are missing or not sufficiently described in the studies, we will contact the corresponding author to obtain the missing information.
Data items. The information technology department will develop two tables for organizing the data: a table that itemizes serotype, and a table that lists antimicrobial resistance to pneumococci. The tables will contain the elements listed in Table 3.
Our review will focus on the scope of the available literature about the serotype distribution of and antibiotic resistance to S. pneumoniae, and the potential impact of PCV13 in China. We do not foresee outcome prioritization, but the approach will be descriptive.
The risk of bias will be determined independently by two study team members. For nonrandomized studies, we will use the ROBINS-I tool10, and for randomized trials, or interventions, we plan to use Cochrane Collaboration's risk-of-bias assessment tool11.
A PRISMA flow chart and the methodological process will be described in detail for transparency. It will indicate the evidence identified and whether it was selected for inclusion in the review. If a study is excluded, the reasons will be provided.
The data will be summarized in the form of a figure, diagram, or table. A narrative summary of the findings will also be included. The strategy for synthesizing the data involves the use of analytical methods and will perform a descriptive synthesis of the data to map the distribution of serotypes and antimicrobial resistance of pneumococci in children under 5 years of age in China after the introduction of PCV13.
The review team is presented in Table 4.
This review is a part of ongoing research in China on the interchangeability of PCV13 with the Cuban vaccine PCV7-TT. When we complete this scoping review, we will consider conducting a systematic review, and we intend to publish the results in an international journal. While preparing the present protocol, we performed preliminary searches to get an idea of the size of the available literature.
Because the scoping review methodology consists of reviewing and synthesizing the data already published, this part of the study is not subject to ethical approval.
This systematic scoping review will be the first to map antimicrobial resistance to and distribution of pneumococcal serotypes in children less than 5 years of age in China after the introduction of PCV13.
It will present an overview of all studies on serotype distribution and antimicrobial resistance, and the analysis will clarify the characteristics and possible differences between the provinces of China.
A search of three large databases will enable us to create a comprehensive map of antimicrobial resistance to and distribution of pneumococcal serotypes in China.
No data are associated with this article.
Views | Downloads | |
---|---|---|
F1000Research | - | - |
PubMed Central
Data from PMC are received and updated monthly.
|
- | - |
Is the rationale for, and objectives of, the study clearly described?
Yes
Is the study design appropriate for the research question?
Yes
Are sufficient details of the methods provided to allow replication by others?
Yes
Are the datasets clearly presented in a useable and accessible format?
Not applicable
References
1. Mo X, Gai Tobe R, Liu X, Mori R: Cost-effectiveness and Health Benefits of Pediatric 23-valent Pneumococcal Polysaccharide Vaccine, 7-valent Pneumococcal Conjugate Vaccine and Forecasting 13-valent Pneumococcal Conjugate Vaccine in China.Pediatr Infect Dis J. 35 (11): e353-e361 PubMed Abstract | Publisher Full TextCompeting Interests: No competing interests were disclosed.
Reviewer Expertise: bioinformatics, biology, immunology
Is the rationale for, and objectives of, the study clearly described?
Yes
Is the study design appropriate for the research question?
Yes
Are sufficient details of the methods provided to allow replication by others?
Yes
Are the datasets clearly presented in a useable and accessible format?
Yes
Competing Interests: No competing interests were disclosed.
Reviewer Expertise: Epidemiology, Occupational Health, Cohort Studies
Alongside their report, reviewers assign a status to the article:
Invited Reviewers | ||
---|---|---|
1 | 2 | |
Version 1 31 Mar 20 |
read | read |
Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list:
Sign up for content alerts and receive a weekly or monthly email with all newly published articles
Already registered? Sign in
The email address should be the one you originally registered with F1000.
You registered with F1000 via Google, so we cannot reset your password.
To sign in, please click here.
If you still need help with your Google account password, please click here.
You registered with F1000 via Facebook, so we cannot reset your password.
To sign in, please click here.
If you still need help with your Facebook account password, please click here.
If your email address is registered with us, we will email you instructions to reset your password.
If you think you should have received this email but it has not arrived, please check your spam filters and/or contact for further assistance.
Comments on this article Comments (0)